These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35398729)

  • 1. Investigation on the chemical space of the substituted triazole thio-benzoxazepinone RIPK1 inhibitors.
    Hao Y; Shao H; Qu Z; Li J; Shi Y; Zhang W; Yu J; Fu P; Zhuang C
    Eur J Med Chem; 2022 Jun; 236():114345. PubMed ID: 35398729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Design of Novel Alkynyl Thio-Benzoxazepinone Receptor-Interacting Protein Kinase-1 Inhibitors: Extending the Chemical Space from the Allosteric to ATP Binding Pockets.
    Quan D; Hou R; Shao H; Zhang X; Yu J; Zhang W; Yuan H; Zhuang C
    J Med Chem; 2023 Feb; 66(4):3073-3087. PubMed ID: 36724216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based bioisosterism design of thio-benzoxazepinones as novel necroptosis inhibitors.
    Xia C; Yao Z; Xu L; Zhang W; Chen H; Zhuang C
    Eur J Med Chem; 2021 Aug; 220():113484. PubMed ID: 33930803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel biaryl benzoxazepinones as dual-mode receptor-interacting protein kinase-1 (RIPK1) inhibitors.
    Xin Y; Dai P; Shao H; Zhuang C; Li J
    Bioorg Med Chem; 2024 Feb; 100():117611. PubMed ID: 38309200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel 2,8-diazaspiro[4.5]decan-1-one derivatives as potent RIPK1 kinase inhibitors.
    Niu A; Lin L; Zhang D; Jiang K; Weng D; Zhou W; Wang J
    Bioorg Med Chem; 2022 Apr; 59():116686. PubMed ID: 35228069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scaffold hopping derived novel benzoxazepinone RIPK1 inhibitors as anti-necroptosis agents.
    Tang J; Wu Y; Zhao W; Qu Z; Yu J; Wang Z; Shi Y
    Bioorg Med Chem; 2023 Aug; 91():117385. PubMed ID: 37364415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Sibiriline derivatives as novel receptor-interacting protein kinase 1 inhibitors.
    Cui N; Li S; Zhang Y; Yin F; Chen X; Luo Z; Wan S; Li X; Kong L; Wang X
    Eur J Med Chem; 2023 Mar; 250():115190. PubMed ID: 36801518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery, optimization and evaluation of isothiazolo[5,4-b]pyridine derivatives as RIPK1 inhibitors with potent in vivo anti-SIRS activity.
    Hao Y; Yang C; Shu C; Li Z; Xia K; Wu S; Ma H; Tian S; Ji Y; Li J; He S; Zhang X
    Bioorg Chem; 2022 Dec; 129():106051. PubMed ID: 36115309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quizartinib inhibits necroptosis by targeting receptor-interacting serine/threonine protein kinase 1.
    Li M; Wei J; Zhu G; Fu S; He X; Hu X; Yu Y; Mou Y; Wang J; You X; Xiao X; Gu T; Ye Z; Zha Y
    FASEB J; 2023 Oct; 37(10):e23178. PubMed ID: 37698367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical contribution of oxidative stress to TNFα-induced necroptosis downstream of RIPK1 activation.
    Shindo R; Kakehashi H; Okumura K; Kumagai Y; Nakano H
    Biochem Biophys Res Commun; 2013 Jun; 436(2):212-6. PubMed ID: 23727581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
    Hou J; Ju J; Zhang Z; Zhao C; Li Z; Zheng J; Sheng T; Zhang H; Hu L; Yu X; Zhang W; Li Y; Wu M; Ma H; Zhang X; He S
    Cell Death Dis; 2019 Jun; 10(7):493. PubMed ID: 31235688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.
    Fauster A; Rebsamen M; Huber KV; Bigenzahn JW; Stukalov A; Lardeau CH; Scorzoni S; Bruckner M; Gridling M; Parapatics K; Colinge J; Bennett KL; Kubicek S; Krautwald S; Linkermann A; Superti-Furga G
    Cell Death Dis; 2015 May; 6(5):e1767. PubMed ID: 25996294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From PERK to RIPK1: Design, synthesis and evaluation of novel potent and selective necroptosis inhibitors.
    Scarpellini C; Valembois S; Goossens K; Vadi M; Lanthier C; Klejborowska G; Van Der Veken P; De Winter H; Bertrand MJM; Augustyns K
    Front Chem; 2023; 11():1160164. PubMed ID: 37090247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis.
    Le Cann F; Delehouzé C; Leverrier-Penna S; Filliol A; Comte A; Delalande O; Desban N; Baratte B; Gallais I; Piquet-Pellorce C; Faurez F; Bonnet M; Mettey Y; Goekjian P; Samson M; Vandenabeele P; Bach S; Dimanche-Boitrel MT
    FEBS J; 2017 Sep; 284(18):3050-3068. PubMed ID: 28715128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Receptor-Interacting Protein Kinase 1 by Novel Benzothiazole Derivatives: Treatment of Acute Lung Injury through the Necroptosis Pathway.
    Zhang X; Han Q; Hou R; Xu L; Zhang W; Xing C; Xue L; Zhuang C
    J Med Chem; 2023 Apr; 66(7):5261-5278. PubMed ID: 36908007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Jun N-terminal kinases differentially regulate TNF- and TLRs-mediated necroptosis through their kinase-dependent and -independent activities.
    Cao M; Chen F; Xie N; Cao MY; Chen P; Lou Q; Zhao Y; He C; Zhang S; Song X; Sun Y; Zhu W; Mou L; Luan S; Gao H
    Cell Death Dis; 2018 Nov; 9(12):1140. PubMed ID: 30442927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opposite Effects of Apoptotic and Necroptotic Cellular Pathways on Rotavirus Replication.
    Soliman M; Seo JY; Baek YB; Park JG; Kang MI; Cho KO; Park SI
    J Virol; 2022 Jan; 96(1):e0122221. PubMed ID: 34668777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RIPK1-RIPK3-MLKL-Associated Necroptosis Drives
    Barbosa LA; Fiuza PP; Borges LJ; Rolim FA; Andrade MB; Luz NF; Quintela-Carvalho G; Lima JB; Almeida RP; Chan FK; Bozza MT; Borges VM; Prates DB
    Front Immunol; 2018; 9():1818. PubMed ID: 30154785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the Raf kinase inhibitor TAK-632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3.
    Chen X; Zhuang C; Ren Y; Zhang H; Qin X; Hu L; Fu J; Miao Z; Chai Y; Liu ZG; Zhang H; Cai Z; Wang HY
    Br J Pharmacol; 2019 Jun; 176(12):2095-2108. PubMed ID: 30825190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis on benzothiazole necroptosis inhibitors with chiral substitutions in the solvent-accessible region of RIP kinase domain.
    Shao H; Xu L; Li G; Wang S; Han T; Zhuang C
    Bioorg Chem; 2023 Aug; 137():106647. PubMed ID: 37270986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.